Volociximab

伏洛昔单抗

Report date: 2023/04/21 09:51:17

Base Information

Drug NameVolociximab
Drug Alias NameEos-200-4M-200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionIntegrin alpha-5/beta-1 antagonists
TargetsIntegrin alpha-5/beta-1
Therapy Area/IndicationsMacular DegenerationNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesOphthotech CoNational Cancer Institute +[6] 
Active IndicationsN/A
Inactive IndicationsMacular DegenerationNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG